tradingkey.logo

Niagen Bioscience Inc

NAGE
查看詳細走勢圖
6.510USD
-0.200-2.98%
收盤 12/23, 16:00美東報價延遲15分鐘
518.45M總市值
24.82本益比TTM

Niagen Bioscience Inc

6.510
-0.200-2.98%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-2.98%

5天

+2.68%

1月

-5.38%

6月

-51.56%

今年開始到現在

+22.71%

1年

+22.83%

查看詳細走勢圖

TradingKey Niagen Bioscience Inc股票評分

單位: USD 更新時間: 2025-12-22

操作建議

Niagen Bioscience Inc當前公司基本面數據相對非常健康,增長潛力很大。當前估值合理,在生物技術與醫療研究行業排名45/404位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價15.80。中期看,股價處於下降通道。近一個月,市場表現一般,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Niagen Bioscience Inc評分

相關信息

行業排名
45 / 404
全市場排名
140 / 4578
所屬行業
生物技術與醫療研究

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 5 分析師
買入
評級
15.800
目標均價
+143.45%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Niagen Bioscience Inc亮點

亮點風險
Niagen Bioscience, Inc., formerly Chromadex Corp., is a global bioscience company. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that is a key regulator of cellular metabolism and is found in every cell of the human body. The Company’s Consumer Products segment provides finished dietary supplement products that contain the Company's proprietary ingredients directly to consumers and distributors and offers NAD+ test kits exclusively to healthcare practitioners. The Ingredients segment develops and commercializes proprietary-based ingredient technologies, including food-grade Niagen and pharmaceutical-grade Niagen, and supplies these ingredients as raw materials to the manufacturers of consumer products and United States FDA-registered 503B outsourcing facilities, respectively. The Analytical Reference Standards and Services segment offers the supply of phytochemical reference standards and other research and development services.
業績高增長
公司營業收入穩步增長,連續3年增長38.23%
業績增長期
公司處於發展階段,最新年度總收入99.60M美元
業績轉盈
公司業績轉盈,最新年度盈利美元
估值高估
公司最新PE估值25.58,處於3年歷史高位
機構加倉
最新機構持股29.97M股,環比增加2.62%
PRFDX持倉
明星投資者PRFDX持倉,最新持倉5.11K股

Niagen Bioscience Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Niagen Bioscience Inc簡介

Niagen Bioscience, Inc., formerly Chromadex Corp., is a global bioscience company. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that is a key regulator of cellular metabolism and is found in every cell of the human body. The Company’s Consumer Products segment provides finished dietary supplement products that contain the Company's proprietary ingredients directly to consumers and distributors and offers NAD+ test kits exclusively to healthcare practitioners. The Ingredients segment develops and commercializes proprietary-based ingredient technologies, including food-grade Niagen and pharmaceutical-grade Niagen, and supplies these ingredients as raw materials to the manufacturers of consumer products and United States FDA-registered 503B outsourcing facilities, respectively. The Analytical Reference Standards and Services segment offers the supply of phytochemical reference standards and other research and development services.
公司代碼NAGE
公司Niagen Bioscience Inc
CEOFried (Robert N)
網址https://www.niagenbioscience.com/

常見問題

Niagen Bioscience Inc(NAGE)的當前股價是多少?

Niagen Bioscience Inc(NAGE)的當前股價是 6.510。

Niagen Bioscience Inc 的股票代碼是什麼?

Niagen Bioscience Inc的股票代碼是NAGE。

Niagen Bioscience Inc股票的52週最高點是多少?

Niagen Bioscience Inc股票的52週最高點是14.690。

Niagen Bioscience Inc股票的52週最低點是多少?

Niagen Bioscience Inc股票的52週最低點是5.160。

Niagen Bioscience Inc的市值是多少?

Niagen Bioscience Inc的市值是518.45M。

Niagen Bioscience Inc的淨利潤是多少?

Niagen Bioscience Inc的淨利潤為8.55M。

現在Niagen Bioscience Inc(NAGE)的股票是買入、持有還是賣出?

根據分析師評級,Niagen Bioscience Inc(NAGE)的總體評級為買入,目標價格為15.800。

Niagen Bioscience Inc(NAGE)股票的每股收益(EPS TTM)是多少

Niagen Bioscience Inc(NAGE)股票的每股收益(EPS TTM)是0.262。
KeyAI